"This is an important issue, particularly as survival rates for breast cancer improve," said study author David G. Darby, MD, chief medical officer of CogState Ltd., an Australian company that developed the cognitive tests used in the studies. "People could be making decisions about whether or not to have chemotherapy based on stories they've heard about 'chemofog' or 'chemobrain.' Hopefully this information will help people make informed decisions."

For Darby's study, 30 women with breast cancer were given cognitive tests before each cycle of chemotherapy and again one month after the final cycle. They were compared to 30 healthy women who were also tested five times about a month apart.

The women with breast cancer had slight problems in attention and learning skills before chemotherapy started. Chemotherapy resulted in only a minor slowing in thinking speed. Three women, or 10 percent, developed cognitive problems during chemotherapy.

"We also found that the women who reported that they had problems with memory, concentration and other cognitive skills were not actually the ones who developed problems as determined by the tests," Darby said.

The second study compared three groups of women: 40 women with breast cancer who had not yet received chemotherapy or radiation; 27 women who had recently had a breast biopsy that was benign, or not cancerous; and 20 breast cancer survivors who had completed treatment at least one year before. All of the women were tested on their cognitive abilities and evaluated for anxiety, depression, their overall quality of life and the amount of social support they had.

On tests of working memory and spatial learning, the women recently diagnosed with breast cancer performed about the same as the women with the recent benign biopsy. However, both groups were slower and less accurate than the breast cancer survivors. In addition, CogState measures of memory and learning for the breast cancer patients did not significantly diminish during the initial stages of treatment. The recently diagnosed women who had better overall quality of life also had better scores on the cognitive tests.

"These results suggest that cognitive difficulties experienced by women with a new breast cancer diagnosis may be related to stress as a result of the diagnosis and other quality-of-life factors, and not simply due to the effects of chemotherapy or radiation," said study author Michael J. Boivin, PhD, MPH, of Michigan State University.

The studies will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12--19, 2008.

Boivin's study was supported by the Templeton Advanced Research Program of the Metanexus Institute.

Darby's study was supported by CogState Ltd., the University of Melbourne, and the Peter MacCallum Cancer Centre.

Note: If no author is given, the source is cited instead.

• Breast Cancer
• Women's Health
• Colon Cancer

• Intelligence
• Gender Difference
• Memory

• Menopause
• Metastasis
• Breast cancer
• Hormone replacement therapy
• Health benefits of tea
• Tumor suppressor gene